Start here
Where are you in your journey?
Choose the path that fits today. We’ll take you to the most useful discussions.
- GLP-1 medication Zepbound, Wegovy, access, side effects, progress, and support.
- Before surgery Compare procedures, plan ahead, and get honest pre-op answers.
- Post-op Recovery, food stages, symptoms, and support.
- Long-term Regain, labs, habits, and life after the honeymoon.
- Revision Explore revision options, complications, and next steps.
FDA approves anti obesity drug
- Replies 7
- Views 3.3k
- Created
- Last Reply
Top Posters In This Topic
-
GreenTealael 2 posts
-
Greendragonfly 2 posts
-
ChubRub 1 post
-
floridagirl23 1 post
Popular Days
Most Popular Posts
-
This is probably spot on
-
I took Ozempic for diabetes prior to surgery and was not able to lose any weight. ??♀️
-
I took Saxenda and only lost a couple of pounds but I would be willing to try this when it becomes available - if my insurance covers it. I think anyone that has more than 50lbs to lose would still be
Novo Nordisk’s newest injectable drug Semaglutide (Wegovy) is now approved as a treatment option for obesity.
It was previously approved and marketed (at lower doses) as Ozempic in 2019 for diabetes. Novo Nordisk is the same company that offers Saxenda (liraglutide).
The CDC states 42.4% of all adults in the U.S. suffer from obesity, defined as having a body mass index at or above 30. A 2019 study in the New England journal of medicine predicts that 1 in 2 adults will be obese by 2030.
This could be a step forward in fighting obesity because of the modality. According to Dr. Anastassios G. Pittas, chief of Endocrinology, Diabetes and Metabolism at Tufts Medical Center, “Semaglutide is a paradigm shift from other obesity medications, because it targets the gut as opposed to the brain."
(Sounds familiar?)
As with all new treatments the hurdles to access includes: steep price tags, insurance approvals, imbalanced clinical trail demographics, medical gatekeepers and lack of long term outcomes.
sources:
https://www.novonordisk-us.com/products/chronic-weight-management.html
https://www.nejm.org/doi/pdf/10.1056/NEJMsa1909301
https://www.fiercepharma.com/pharma/novo-nordisk-s-semaglutide-snags-hotly-anticipated-greenlight-obesity
https://www.google.com/amp/s/abcnews.go.com/amp/Health/newly-approved-drug-heralded-game-changer-growing-national/story%3fid=78065574
https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-semaglutide-gets-us-fda-approval-obesity-treatment-2021-06-04/
https://www.google.com/amp/s/amp.detroitnews.com/amp/7549263002
Edited by GreenTealael